NCT06381258

Brief Summary

The aim of our study is to evaluate the effect of PE and FGR on fetal cardiac function. Pregnancies with preeclampsia and FGR, and preeclampsia with normal fetal growth are evaluated by echocardiography and compared with uncomplicated pregnancies.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
72

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 19, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 24, 2024

Completed
6 days until next milestone

Study Start

First participant enrolled

April 30, 2024

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2024

Completed
11 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 12, 2024

Completed
Last Updated

December 24, 2024

Status Verified

April 1, 2024

Enrollment Period

7 months

First QC Date

April 19, 2024

Last Update Submit

December 19, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Cardiac systolic function

    Measurement of ejection fraction in percent % (high is good, low is bad)

    4 months

Secondary Outcomes (1)

  • Cardiac diastolic function

    4 months

Study Arms (2)

Patients with preeclampsia

Fetal ultrasound( echocardiography).Measurements will be performed using conventional pulsed-wave Doppler and M mode cross sectional image of the fetal thorax at the level of the 4-chamber view with an apical projection of the heart is obtained. Measurements of the ventricle at diastole and systole are obtained, and using the relationship between these measurements, calculations are performed to determine the ejection fraction (EF) (\[diastole measurement-systole measurement\]/diastole) measurement and shortening fraction ( SF) for both right \& left ventricles. Assessment of ventricular diastolic function through measuring E-wave (early ventricular filling) and A wave (active atrial contraction - late ventricular filling) peak velocities and the ratio between them (E/A ratio) as an index will be performed for both mitral valve (MV) and tricuspid valve (TV)

Procedure: Ultrasound

Patients without preeclampsia

Fetal ultrasound (echocardiography).Measurements will be performed using conventional pulsed-wave Doppler and M mode cross sectional image of the fetal thorax at the level of the 4-chamber view with an apical projection of the heart is obtained. Measurements of the ventricle at diastole and systole are obtained, and using the relationship between these measurements, calculations are performed to determine the ejection fraction (EF) (\[diastole measurement-systole measurement\]/diastole) measurement and shortening fraction ( SF) for both right \& left ventricles. Assessment of ventricular diastolic function through measuring E-wave (early ventricular filling) and A wave (active atrial contraction - late ventricular filling) peak velocities and the ratio between them (E/A ratio) as an index will be performed for both MV and TV

Procedure: Ultrasound

Interventions

UltrasoundPROCEDURE

Fetal echocardiography using ultrasound device

Patients with preeclampsiaPatients without preeclampsia

Eligibility Criteria

Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Group A : patients with preeclampsia (either with FGR or normal growth) Group B : patients without preeclampsia (16 cases)

You may qualify if:

  • Pregnant women more than or equals 28 weeks
  • Preeclampsia defined as systolic blood pressure 140 mm Hg and/or diastolic blood pressure 90 mm Hg
  • Fetus with normal growth or with growth restriction

You may not qualify if:

  • congenital malformations
  • intrauterine infection
  • multiple pregnancies
  • fetuses of mothers treated with a tocolytic agent
  • fetuses with abnormal heart rates (tachycardia or bradycardia)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Women's Health Hospital

Asyut, Egypt

Location

MeSH Terms

Conditions

Fetal Growth Retardation

Interventions

High-Energy Shock Waves

Condition Hierarchy (Ancestors)

Fetal DiseasesPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesGrowth DisordersPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Ultrasonic WavesSoundRadiation, NonionizingRadiationPhysical Phenomena

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of Obs& Gyn. Specialist of Urogynecology

Study Record Dates

First Submitted

April 19, 2024

First Posted

April 24, 2024

Study Start

April 30, 2024

Primary Completion

December 1, 2024

Study Completion

December 12, 2024

Last Updated

December 24, 2024

Record last verified: 2024-04

Data Sharing

IPD Sharing
Will not share

Locations